Fam Med - SUTM Ambu/CF(1-3) Flashcards
HTN - classification (adult >18)
Normal—SBP<120 and DBP<80
Elevated—SBP 120-139 or DBP 80-89 (pre-HTN => require lifestyle modification)
Stage I—SBP 140-159 or DBP 90-99 (HTN definition BP > 130/80)
StageII—SBP≥ 160 or DBP≥100
HTN - HTN urgency and emergency
Urgency (severe) SBP >180 and/or DBP >120 - in an asymptomatic patient
Emergency = severe HTN with end-organ damage (neurologic, MI, aortic dissection)
HTN - antihypertensive meds for pregnant women
Contraindicated - ACEi, ARB, thiazide, Ca++ channel blockers
Safe: ß-blockers, hydralazine
HTN- what to do when patient presents with moderate-to-severe HTN?
Initiating therapy right away - DON’T wait 1-2 months to confirm diagnosis and start treatment
HTN - Thiazide side-effects
HYPOKALEMIA
hyperuricemia, hyperglycemia, elevation of cholesterol and triglyceride levels, metabolic alkalosis, hyperuricemia, hypomagnesemia
HTN - ß-blockers side-effects
Bradycardia, bronchospasm, sleep disturbances (insomnia), fatigue, may increase TGs and decrease HDL, depression, sedation, may mask hypoglycemic symptoms in diabetic patients on insulin
HTN - ACEi side-effects
Acute renal failure, hyperkalemia, dry cough, angioedema, skin rash, altered sense of taste
HTN - Ca++ channel blockers side effects
Dihydropyridines (e.g., amlodipine): peripheral edema
Nondihydropyridines (e.g., verapamil, diltiazem): heart block
HTN - initial mono-therapy option? Is there any difference?
Thiazide, ACEi, ARBs, and Ca++ channel blockers (dihydropyridine)
There is little difference.
Most patients eventually need more than 1 drug to attain goal BP
HTN - what to do if “white coat HTN” is suspected?
Twenty-four–hour ambulatory blood pressure monitoring is the most effective.
Home blood pressure monitoring is an alternative.
HTN - Principles of treatment - target BP
≤60 => BP ≤ 140/90
>60 => BP ≤ 150/90
HTN - Principles of treatment - What to do when mono-therapy is ineffective?
- Increase dose to maximum
- Add 2nd meds (ACCOMPLISH trial show ACEi and CCB combination is effective) and increase dose of each to max
- Consider 3rd agent and referral to HTN specialist
HTN - Lipid screening for pt with and without CAD risk
With CAD risk (family history, obesity) => screen with fasting lipid profile every 5 years starting age 20
Without CAD risk => screen women ≥45y/o and men ≥35y/o
Hyperlipidemia - Risk factors for CAD in patient with hyperlipidemia - Clinical pearl
Current cigarette smoking (dose-dependent risk)
HTN
Diabetes mellitus
Low HDL cholesterol (<35 mg/dL); high HDL (>60 mg/dL) is a NEGATIVE risk factor (subtract 1 from total)
Male: >45 years of age Female: >55 years of age
Male gender—if you count as a risk factor, do not count age Family history of premature CAD
MI/sudden death in male first-degree relative <55 years of age MI/sudden death in female first-degree relative <65 years of age
Hyperlipidemia - Risk factors - Diet
Saturated fatty acid and cholesterol => Elevated LDL and total cholesterol
High-calorie diets => increase triglyceride (TG) levels
Alcohol => increase TG levels and HDL levels
Hyperlipidemia - Risk factors - Medications
Thiazides—increase LDL, total cholesterol, TG (VLDL)
β-Blockers (propranolol)—increase TGs (VLDL) and lower HDL
Estrogens—TG further increased in patients with hypertriglyceridemia
Corticosteroids and HIV protease inhibitors => elevate serum lipids
Hyperlipidemia - Potency of statins
High intensity: atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg
Moderate intensity: atorvastatin 10 to 20 mg, rosuvastatin 5 to 10 mg, simvastatin 20 to 40 mg, lovastatin 40 mg, pravastatin 40 to 80 mg, fluvastatin XL 80 mg (or 40 mg twice daily), pitavastatin 2 to 4 mg
Low intensity: simvastatin 10 mg, pravastatin 10 to 20 mg, lovastatin 20 mg, fluvastatin 20 to 40 mg, pitavastatin 1 mg
Hyperlipidemia - Four Categories of Patients Aged >21 yrs Who Benefit From Statin Therapy
Clinical ASCVD => High-intensity statin
LDL cholesterol ≥190 mg/dL => High-intensity statin
Diabetic patients aged 40–75 yrs with LDL cholesterol 70–
189 mg/dL
ASCVD risk score <7.5% => moderate-intensity
ASCVD risk score ≥7.5% => high-intensity statin
Nondiabetic patients aged 40–75 yrs with LDL cholesterol 70–189 mg/dL
ASCVD risk score ≥7.5% => moderate- to high- intensity statin
Hyperlipidemia - Dyslipidemia Syndrome
Type I: exogenous hyperlipidemia => chylomicron => Diet
Type IIa: familial hypercholesterolemia => LDL => Statins/Niacin/Cholestyramine
Type IIb: combined hyperlipoproteinemia => LDL+VLDL => Statins/Niacin/Gemfibrozil
Type III: Familial dysbetalipoproteinemia => IDL => Gemfibrozil/Niacin
Type IV: Endogenous hyperlipidemia => VLDL => Niacin/Gemfibrozil/Statins
Type V: Familial hypertriglyceridemia => VLDL+chylomicron => Niacin/Gemfibrozil
Case File - Health maintenance - Level of prevention
Primary: prevent disease before it occurs (vaccines, education/exercise. removal of colon polyps…)
Secondary: promote early detection of disease (mammogram, eye exam for glaucoma…)
Tertiary: therapeutic and rehabilitative once disease is diagnosed (meds, stroke rehab, chronic pain management…)